Jan Oldenburg
Norway
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 87 publications
Artificial intelligence in prostate MRI: Comparative diagnostic performance in a high-prevalence cohort.
Journal: Acta radiologica (Stockholm, Sweden : 1987)
Published: July 27, 2026
A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide with placebo plus enzalutamide for patients with advanced prostate cancer.
Journal: Future oncology (London, England)
Published: June 09, 2026
A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer and changes in specific DNA repair genes.
Journal: Future oncology (London, England)
Published: June 04, 2026
EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2026 Update: Treatment of Relapsing and Metastatic Prostate Cancer.
Journal: European urology
Published: March 05, 2026
EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2026 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent.
Journal: European urology
Published: March 05, 2026
Corrigendum to "Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: Safety analyses from the randomized, placebo-controlled, phase III TALAPRO-2 study" [Eur J Cancer 213 (December) (2024) 115078].
Journal: European journal of cancer (Oxford, England : 1990)
Published: November 19, 2025
Explainable AI Model Reveals Informative Mutational Signatures for Cancer-Type Classification.
Journal: Cancers
Published: April 17, 2025
Impact of calcifications on paravalvular leakage by transcatheter aortic valve prostheses: findings from a new in silico clinical trial framework.
Journal: Biomechanics and modeling in mechanobiology
Published: March 13, 2025
Efficacy of Anti-PD-(L)1 Immunotherapy in Patients with DNA Mismatch Repair-deficient Metastatic Castration-resistant Prostate Cancer.
Journal: European urology oncology
Published: February 12, 2025
Talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer and changes in specific DNA repair genes: a plain language summary of the results from the TALAPRO-2 study.
Journal: Future oncology (London, England)
Published: January 30, 2025
Prognostic Value of the Circulating Tumor DNA Fraction in Metastatic Castration-resistant Prostate Cancer: Results from the ProBio Platform Trial.
Journal: European urology oncology
Published: January 22, 2025
Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial.
Journal: Lancet (London, England)
Published: January 17, 2025
Last Updated: 09/26/2026